Strategies to Reduce Addiction Stigma Among Health Professionals

Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Professionals: A Randomized Experiment

The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.

Study Overview

Detailed Description

This randomized experiment evaluated the impact of exposure to message frames communicating the importance of non-stigmatizing language regarding addiction and the effectiveness of medication treatment for opioid use disorder delivered through a visual campaign alone or through a visual campaign in addition to a narrative vignette from the perspective of one of three messengers (a person with opioid use disorder, a clinician, or a health system leader) on attitudes toward people with opioid use disorder and medications for treating opioid use disorder among a national sample of health professionals.

Study Type

Interventional

Enrollment (Actual)

1842

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21205
        • Johns Hopkins Bloomberg School of Public Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • employed as health professional in the United States, including clinicians (e.g., physicians, nurses, physician assistants, pharmacists, and optometrists), technicians and technologists (e.g., laboratory technologist or technician, emergency medical technician, paramedic, licensed practical or licensed vocational nurse, medical records or health information technician, etc.), health aids and assistants (e.g., nursing aide, home health aide, medical assistant, pharmacy aide, phlebotomist, etc.)
  • participant in existing web-based survey panel (IPSOS's KnowledgeNetworks panel and partner opt-in panel)

Exclusion Criteria:

  • not employed in health profession
  • not able to complete experiment and survey in English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: No exposure control group
This group was not exposed to any message frame.
Experimental: Words Matter - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
Experimental: Medication Treatment Works - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rating of willingness to have person with opioid use disorder marry into their family
Time Frame: Measured immediately post-exposure to message frame intervention
Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder marry into the family. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person with opioid use disorder as a neighbor
Time Frame: Measured immediately post-exposure to message frame intervention
Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder as a neighbor. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that opioid use disorder is a medical condition
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Opioid use disorder is a chronic medical condition like diabetes mellitus" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that individuals with opioid use disorder are to blame
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Individuals with opioid use disorder only have themselves to blame for their problem" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of support for increasing government spending on opioid use disorder treatment
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of support for increasing government spending on treatment of opioid use disorder with 5 indicating strongly favoring and 1 indicating strongly opposing. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Feeling thermometer measure of warmth toward people with opioid use disorder
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of warmth felt toward people with opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stigmatizing Language - Addict
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "addict" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - Substance abuse
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "substance abuse" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - dirty
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "'dirty' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - clean
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "'clean' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - addicted baby
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "addicted baby" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - person with substance use disorder
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "person with substance use disorder" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - substance use
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "substance use" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - negative test result
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "negative test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - positive test result
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "positive test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - baby born with neonatal opioid withdrawal syndrome
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "baby born with neonatal opioid withdrawal syndrome" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Willingness to sign pledge committing to using non-stigmatizing language
Time Frame: Measured immediately post-exposure to message frame intervention
Binary (yes/no) measure of whether participant is willing to sign a pledge committing to using non-stigmatizing language related to substance use disorder in clinical settings. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Perception of opioid use disorder treatment effectiveness
Time Frame: Measured immediately post-exposure to message frame intervention
Participant perception of whether there is a treatment for opioid use disorder that is effective for a long period of time (three close-ended response options: yes, there is a treatment; no, there isn't such a treatment; don't know). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication marry into their family
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication to treat opioid use disorder marry into family. Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder marry into the family. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication marry as a neighbor
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication to treat opioid use disorder as a neighbor. Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder as a neighbor. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of strength/weakness of person taking medication
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of strength/weakness of person taking medication to treat opioid use disorder on 5-point Likert scale with 5 indicating strong and 1 indicating weak. This is a semantic differential measure. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that recovery is possible
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Most people with opioid use disorder will, with medication treatment, get well and return to productive lives" on a 5-point Likert scale with 5 indicating strongly disagree and 1 indicating strongly agree. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Feeling thermometer measure of warmth toward people taking medication
Time Frame: Measured immediately post-exposure to message frame intervention
Rating of warmth felt toward people taking medication to treat opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alene Kennedy-Hendricks, PhD, Johns Hopkins Bloomberg School of Public Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2020

Primary Completion (Actual)

November 30, 2020

Study Completion (Actual)

November 30, 2020

Study Registration Dates

First Submitted

October 28, 2021

First Submitted That Met QC Criteria

November 8, 2021

First Posted (Actual)

November 19, 2021

Study Record Updates

Last Update Posted (Actual)

November 19, 2021

Last Update Submitted That Met QC Criteria

November 8, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe